7 results
Search Results
2. Efficacy and safety of a new 450 mg/ml florfenicol formulation administered intramuscularly in the treatment of bacterial bovine respiratory disease.
- Author
-
Thiry, J., Rubion, S., Sarasola, P ., Bonnier, M., Hartmann, M., and de Haas, V.
- Subjects
EXCIPIENTS ,BOS ,ANIMAL diseases ,MYCOPLASMA diseases ,CONTROL groups ,RESPIRATORY diseases ,VETERINARY medicine ,DISEASES - Abstract
The objective of the study was the safety and efficacy evaluation of a new 450 mg/ml florfenicol formulation in the treatment of naturally occurring respiratory disease when administered intramuscularly, compared with a positive control group treated with the well-established 300 mg/ml formulation. A total of 174 calves, selected from five sites in France and Spain, aged from 1 to 17 months, showing severe signs of respiratory disease, were randomly assigned to treatment with either the 300 mg/ml (3 ml/45 kg; Nuflor; MSD Animal Health) or 450 mg/ml (2 ml/45 kg; Nuflor Minidose; MSD Animal Health) florfenicol formulation, both administered intramuscularly twice, two days apart. Animals were clinically observed daily for 14 days following treatment initiation. The predominant pathogens present in pretreatment respiratory tract samples were Mannheimia haemolytica and Pasteurella multocida. Mycoplasma bovis and Histophilus somni were also present. All isolates were subjected to in vitro sensitivity testing and found susceptible to florfenicol. In both treatment groups, rectal temperature dropped and clinical index (depression and respiratory signs) significantly improved (P<0.05) after treatment. As a result, 97.7 per cent of the 450 mg/ml florfenicol formulation-treated animals were considered treatment successes on day 5. On day 14, 67.82 per cent of the animals were classified as treatment successes and among them 63.22 per cent were cured. The intramuscular injection of the new 450 mg/ml florfenicol formulation was found equally efficacious as the original 300 mg/ml formulation. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
3. Incidence of histomonosis in turkeys in France since the bans of dimetridazole and nifursol.
- Author
-
Callait-Cardinal, M.-P., Leroux, S., Venereau, E., Chauve, C. M., Le Pottier, G., and Zenner, L.
- Subjects
TURKEYS ,MORTALITY ,ANIMAL health ,VETERINARY medicine ,DISEASES - Abstract
Between April 2003 and March 2005, 113 outbreaks of histomonosis were recorded in standard turkey farms in France, and 15 cases were recorded in turkey breeding centres. Most of the cases were in north-west France, the principal farming area for turkeys. The majority of the cases occurred during the hottest months, from April to September. Large numbers of cases occurred among birds from four to eight weeks of age, but there were some cases in three-week-old birds and some in birds up to 17 weeks of age. In most of the standard turkey flocks the mortality was less than loper cent, but it was above 30 per cent in nearly 20 per cent of the outbreaks. In the breeding flocks, the average mortality was 60!2 per cent. The size of the flocks, the sex of the birds and the age at which the first clinical signs appeared did not seem to influence the mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
4. Estimates of the prevalence of transmissible spongiform encephalopathies in sheep and goats in France in 2002.
- Author
-
Morignat, E., Cazeau, G., Biacabe, A.-G., J.-L. Vinard, Bencsik, A., Madec, J-Y., Ducrot, C., Baron, T., and Calavas, D.
- Subjects
CHRONIC wasting disease ,COMMUNICABLE diseases in animals ,INFECTIOUS disease transmission ,SHEEP diseases ,GOAT diseases ,VETERINARY medicine - Abstract
An active surveillance programme for transmissible spongiform encephalopathies (TSES) in sheep and goats was implemented in France in 2002 at abattoirs and rendering plants. The analysis of the results of this programme highlighted three biases: a potentially non-random sampling scheme in both rendering plants and abattoirs, a heterogeneous geographical sampling ratio, and the use of two diagnostic tests of unequal sensitivity. Simulations were run to estimate the prevalence of TSES by taking these biases into account. A comparison of the prevalence of TSES calculated from the raw data with the simulation results showed that the effects of non-random sampling were minor in comparison with the effects of the heterogeneous geographical sampling ratio and the use of two diagnostic tests. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
5. Efficacy of danofloxacin in the treatment of respiratory disease in European cattle.
- Author
-
Rowan, T.G., Sarasola, P., Sunderland, S.J., Giles, C.J., and Smith, D.G.
- Subjects
TREATMENT of cattle diseases ,LIVESTOCK diseases ,ANTIBIOTICS ,VETERINARY medicine ,RESPIRATORY diseases - Abstract
The efficacy of an injectable formulation of danofloxacin (180 mg/ml) in the treatment of naturally occurring bovine respiratory disease was evaluated in field studies on farms in France, Ireland and the United Kingdom. Cattle aged one week to 15 months with clinical respiratory disease were randomly allocated to treatment with 6 mg/kg danofloxacin or 10 mg/kg tilmicosin, administered by a single subcutaneous injection on day 0. A second injection of danofloxacin was administered on day 2, only if predefined clinical criteria were met. Mannheimia haemolytica, Pasteurella multocida and Haemophilus somnus were isolated from pretreatment nasopharyngeal swabs taken on all the farms. After the treatment, there was a more rapid improvement in the clinical response of the 178 animals treated with danofloxacin by day 2 (P<0.01) than in the 90 treated with tilmicosin. For both treatments, there were similar significant (P<0.001) reductions in the mean rectal temperature and severity of clinical signs of abnormal respiration and depression, on days 4 and 10 compared with day 0; 78.1 per cent of the animals treated with danofloxacin and 78.5 per cent of those treated with tilmicosin completed the studies. Danofloxacin 18 per cent was clinically safe and as effective as tilmicosin in the treatment of bovine respiratory disease. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
6. First outbreak of Trypanosoma evansi in camels in metropolitan France.
- Author
-
Desquesnes, M., Bossard, G., Patrel, D., Herder, S., Patout, O., Lepetitcolin, E., Thevenon, S., Berthier, D., Pavlovic, D., Brugidou, R., Jacquiet, P., Schelcher, F., Faye, B., Touratier, L., and Cuny, G.
- Subjects
TRYPANOSOMA ,CAMELS ,FARMS ,VETERINARY medicine - Abstract
The first outbreak of trypanosomosis caused by Trypanosoma evansi in camels in France was reported on a farm in the Aveyron Department. Five camels were imported from the Canary Islands to the farm in early July 2006, and trypanosomes were observed on a stained blood smear from one of them, which died in October. On further investigations, trypanosomes were observed in the blood of five camels, three of them indigenous to the farm and two that had been imported. On the basis of microscopical examination (morphological criteria and measurements) and serological results based on the card agglutination Tevansitest and PCR typing, the parasites were identified as Tevansi. After treatment with melarsomine, the infected camels rapidly became negative by parasitological tests and were negative two to four months later by serological tests. The parasite was probably transmitted by tabanids and Stomoxys calcitrans, which were abundant in July to September 2006. No parasites were observed in other animals on the farm or on neighbouring farms, but some of the sheep on these farms were positive by PCR or serology. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
7. Results of active surveillance for BSE in France.
- Subjects
REPORTING of diseases ,BOVINE spongiform encephalopathy ,VIRUS diseases in cattle ,VETERINARY medicine - Abstract
Reports on the introduction of mandatory reporting system for bovine spongiform encephalopathy by French government.
- Published
- 2004
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.